Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802084 | 1.00 | KDM4E (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL29416612 | 1.00 | KDM4E (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL16661674 | 1.00 | KDM4E (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL120159 | 1.00 | KDM4E (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL12846200 | 1.00 | KDM4E (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL120160 | 1.00 | KDM4E (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL1797280 | 0.94 | SMN1; SMN2 (0.33) | KDM4EHTTSMN1; SMN2F2F10 | |
| SCHEMBL28721787 | 0.93 | CA1 (0.32) | KDM4ECA1CA2HTTRAB9A | |
| SCHEMBL12846257 | 0.93 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL12846202 | 0.92 | PDK2 (0.34) | KDM4ECA1CA2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380569-A1 | Process for Preparation of Optically Enriched Isoxazolines | BASF SE (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20210340113-A1 | PROCESS FOR PREPARATION OF OPTICALLY ENRICHED ALDOL COMPOUNDS | BASF SE (DE) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380569-A1 | Process for Preparation of Optically Enriched Isoxazolines | CYP11B2, CYP11B1, CYP3A7 | KDM4E 1108/4885CA1 2720/4885CA2 3042/4885 |
| US-20210340113-A1 | PROCESS FOR PREPARATION OF OPTICALLY ENRICHED ALDOL COMPOUNDS | ADH5, ALDOA, ACACB | KDM4E 746/4885CA1 2299/4885CA2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.